<DOC>
	<DOCNO>NCT00468169</DOCNO>
	<brief_summary>The main purpose study explore compare efficacy Cetuximab ( ERBITUX® ) add two concurrent chemoradiotherapy platform different intensity locally advanced head neck cancer .</brief_summary>
	<brief_title>Cetuximab ( ERBITUX® ) Added Two Concurrent Chemoradiotherapy Platforms Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Age 18 old Stage III IV head neck cancer Patients squamous cell carcinoma unknown primary suspect origin head neck area No prior chemotherapy radiotherapy Prior surgical therapy incisional excisional biopsy organsparing procedure Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 Normal organ marrow function Unequivocal demonstration metastatic disease Known severe hypersensitivity drug use study Treatment nonapproved investigational drug within 30 day Day 1 Incomplete heal previous surgery Pregnancy breast feeding Uncontrolled intercurrent illness include Patients clinically significant pulmonary dysfunction , cardiomyopathy , history clinically significant CHF Acute hepatitis know HIV Severe baseline neurologic deficit Prior therapy specifically directly target EGFR pathway Prior severe infusion reaction monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Cetuximab</keyword>
	<keyword>Erbitux</keyword>
	<keyword>locally</keyword>
	<keyword>advanced</keyword>
	<keyword>head</keyword>
	<keyword>neck</keyword>
	<keyword>cancer</keyword>
	<keyword>neoplasm</keyword>
	<keyword>squamous</keyword>
	<keyword>carcinoma</keyword>
	<keyword>lymphoepithelioma</keyword>
</DOC>